Pfizer, Flagship Pioneering partner to invest $100m in drug discovery
Under the agreement, Flagship and Pfizer will each invest $50m upfront to assess opportunities to develop 10 single-asset…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jul 23
Under the agreement, Flagship and Pfizer will each invest $50m upfront to assess opportunities to develop 10 single-asset…
19 Jul 23
Emory Hernandez Valadez claims that heavy exposure to the company's talc starting in his early years led to…
19 Jul 23
The products involved in the deal include FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and non-prescription brands FRESHKOTE and…
19 Jul 23
The reorganisation will focus on consolidating functional roles within the group companies to strengthen various aspects, including business…
19 Jul 23
First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication
19 Jul 23
In a Phase 2 study, navacaprant (NMRA-140) monotherapy demonstrated statistically significant and clinically meaningful reductions in symptoms of…
19 Jul 23
New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers. Launch…
18 Jul 23
DTx Pharma is engaged in developing small interfering RNA (siRNA) therapeutics for neuroscience indications, leveraging its FALCON platform,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jul 23
In the trial, acoramidis showed statistically significant improvement in the primary endpoint by a Win Ratio of 1.8…
18 Jul 23
The US health regulator gave its approval after the Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted in favour…